Levonorgestrel-releasing intrauterine system versus endometrial ablation for heavy menstrual bleeding.


Journal

American journal of obstetrics and gynecology
ISSN: 1097-6868
Titre abrégé: Am J Obstet Gynecol
Pays: United States
ID NLM: 0370476

Informations de publication

Date de publication:
02 2021
Historique:
received: 12 03 2020
revised: 30 06 2020
accepted: 10 08 2020
pubmed: 17 8 2020
medline: 17 2 2021
entrez: 16 8 2020
Statut: ppublish

Résumé

Heavy menstrual bleeding affects the physical functioning and social well-being of many women. The levonorgestrel-releasing intrauterine system and endometrial ablation are 2 frequently applied treatments in women with heavy menstrual bleeding. This study aimed to compare the effectiveness of the levonorgestrel-releasing intrauterine system with endometrial ablation in women with heavy menstrual bleeding. This multicenter, randomized controlled, noninferiority trial was performed in 26 hospitals and in a network of general practices in the Netherlands. Women with heavy menstrual bleeding, aged 34 years and older, without a pregnancy wish or intracavitary pathology were randomly allocated to treatment with either the levonorgestrel-releasing intrauterine system (Mirena) or endometrial ablation, performed with a bipolar radiofrequency device (NovaSure). The primary outcome was blood loss at 24 months, measured with a Pictorial Blood Loss Assessment Chart score. Secondary outcomes included reintervention rates, patient satisfaction, quality of life, and sexual function. We registered 645 women as eligible, of whom 270 women provided informed consent. Of these, 132 women were allocated to the levonorgestrel-releasing intrauterine system (baseline Pictorial Blood Loss Assessment Chart score, 616) and 138 women to endometrial ablation (baseline Pictorial Blood Loss Assessment Chart score, 630). At 24 months, mean Pictorial Blood Loss Assessment Chart scores were 64.8 in the levonorgestrel-releasing intrauterine system group and 14.2 in the endometrial ablation group (difference, 50.5 points; 95% confidence interval, 4.3-96.7; noninferiority, P=.87 [25 Pictorial Blood Loss Assessment Chart point margin]). Compared with 14 women (10%) in the endometrial ablation group, 34 women (27%) underwent a surgical reintervention in the levonorgestrel-releasing intrauterine system group (relative risk, 2.64; 95% confidence interval, 1.49-4.68). There was no significant difference in patient satisfaction and quality of life between the groups. Both the levonorgestrel-releasing intrauterine system and endometrial ablation strategies lead to a large decrease in menstrual blood loss in women with heavy menstrual bleeding, with comparable quality of life scores after treatment. Nevertheless, there was a significant difference in menstrual blood loss in favor of endometrial ablation, and we could not demonstrate noninferiority of starting with the levonorgestrel-releasing intrauterine system. Women who start with the levonorgestrel-releasing intrauterine system, a reversible and less invasive treatment, are at an increased risk of needing additional treatment compared with women who start with endometrial ablation. The results of this study will enable physicians to provide women with heavy menstrual bleeding with the evidence to make a well-informed decision between the 2 treatments.

Sections du résumé

BACKGROUND
Heavy menstrual bleeding affects the physical functioning and social well-being of many women. The levonorgestrel-releasing intrauterine system and endometrial ablation are 2 frequently applied treatments in women with heavy menstrual bleeding.
OBJECTIVE
This study aimed to compare the effectiveness of the levonorgestrel-releasing intrauterine system with endometrial ablation in women with heavy menstrual bleeding.
STUDY DESIGN
This multicenter, randomized controlled, noninferiority trial was performed in 26 hospitals and in a network of general practices in the Netherlands. Women with heavy menstrual bleeding, aged 34 years and older, without a pregnancy wish or intracavitary pathology were randomly allocated to treatment with either the levonorgestrel-releasing intrauterine system (Mirena) or endometrial ablation, performed with a bipolar radiofrequency device (NovaSure). The primary outcome was blood loss at 24 months, measured with a Pictorial Blood Loss Assessment Chart score. Secondary outcomes included reintervention rates, patient satisfaction, quality of life, and sexual function.
RESULTS
We registered 645 women as eligible, of whom 270 women provided informed consent. Of these, 132 women were allocated to the levonorgestrel-releasing intrauterine system (baseline Pictorial Blood Loss Assessment Chart score, 616) and 138 women to endometrial ablation (baseline Pictorial Blood Loss Assessment Chart score, 630). At 24 months, mean Pictorial Blood Loss Assessment Chart scores were 64.8 in the levonorgestrel-releasing intrauterine system group and 14.2 in the endometrial ablation group (difference, 50.5 points; 95% confidence interval, 4.3-96.7; noninferiority, P=.87 [25 Pictorial Blood Loss Assessment Chart point margin]). Compared with 14 women (10%) in the endometrial ablation group, 34 women (27%) underwent a surgical reintervention in the levonorgestrel-releasing intrauterine system group (relative risk, 2.64; 95% confidence interval, 1.49-4.68). There was no significant difference in patient satisfaction and quality of life between the groups.
CONCLUSION
Both the levonorgestrel-releasing intrauterine system and endometrial ablation strategies lead to a large decrease in menstrual blood loss in women with heavy menstrual bleeding, with comparable quality of life scores after treatment. Nevertheless, there was a significant difference in menstrual blood loss in favor of endometrial ablation, and we could not demonstrate noninferiority of starting with the levonorgestrel-releasing intrauterine system. Women who start with the levonorgestrel-releasing intrauterine system, a reversible and less invasive treatment, are at an increased risk of needing additional treatment compared with women who start with endometrial ablation. The results of this study will enable physicians to provide women with heavy menstrual bleeding with the evidence to make a well-informed decision between the 2 treatments.

Identifiants

pubmed: 32795428
pii: S0002-9378(20)30844-9
doi: 10.1016/j.ajog.2020.08.016
pii:
doi:

Substances chimiques

Contraceptive Agents, Hormonal 0
Levonorgestrel 5W7SIA7YZW

Banques de données

NTR
['NL2842']

Types de publication

Comparative Study Equivalence Trial Journal Article Multicenter Study Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

187.e1-187.e10

Informations de copyright

Copyright © 2020 The Authors. Published by Elsevier Inc. All rights reserved.

Auteurs

Pleun Beelen (P)

Department of Obstetrics and Gynaecology, Máxima MC, Veldhoven, Netherlands; Department of General Practice, University of Maastricht, Maastricht, Netherlands. Electronic address: pleun.beelen@gmail.com.

Marian J van den Brink (MJ)

Department of General Practice and Elderly Care Medicine, University of Groningen, University Medical Centre Groningen, Groningen, Netherlands.

Malou C Herman (MC)

Department of Obstetrics and Gynaecology, Jeroen Bosch Hospital, 's-Hertogenbosch, Netherlands.

Peggy M A J Geomini (PMAJ)

Department of Obstetrics and Gynaecology, Máxima MC, Veldhoven, Netherlands.

Janny H Dekker (JH)

Department of General Practice and Elderly Care Medicine, University of Groningen, University Medical Centre Groningen, Groningen, Netherlands.

Ruben G Duijnhoven (RG)

Department of Obstetrics and Gynaecology, Academic Medical Centre, Amsterdam, Netherlands.

Nienke Mak (N)

Department of General Practice, University of Maastricht, Maastricht, Netherlands.

Hannah S van Meurs (HS)

Department of Obstetrics and Gynaecology, Academic Medical Centre, Amsterdam, Netherlands.

Sjors F Coppus (SF)

Department of Obstetrics and Gynaecology, Máxima MC, Veldhoven, Netherlands.

Jan Willem van der Steeg (JW)

Department of Obstetrics and Gynaecology, Jeroen Bosch Hospital, 's-Hertogenbosch, Netherlands.

Heleen P Eising (HP)

Department of Obstetrics and Gynecology, Gelre Hospital, Apeldoorn, Netherlands.

Diana S Massop-Helmink (DS)

Department of Obstetrics and Gynaecology, Medisch Spectrum Twente, Twente, Netherlands.

Ellen R Klinkert (ER)

Department of Obstetrics and Gynaecology, University Medical Centre Groningen, Groningen, Netherlands.

Theodoor E Nieboer (TE)

Department of Obstetrics and Gynaecology, Radboud University Medical Centre, Nijmegen, Netherlands.

Anne Timmermans (A)

Department of Obstetrics and Gynaecology, Academic Medical Centre, Amsterdam, Netherlands.

Lucet F van der Voet (LF)

Department of Obstetrics and Gynecology, Deventer Hospital, Deventer, Netherlands.

Sebastiaan Veersema (S)

Department of Reproductive Medicine and Gynecology, University Medical Center Utrecht, Utrecht, Netherlands.

Nicol A C Smeets (NAC)

Department of Obstetrics and Gynecology, Zuyderland Medical Centre, Heerlen, Netherlands.

Joke M Schutte (JM)

Department of Obstetrics and Gynecology, Isala Hospital, Zwolle, Netherlands.

Marchien van Baal (M)

Department of Obstetrics and Gynecology, Flevo Hospital, Almere, Netherlands.

Patrick M Bossuyt (PM)

Department of Clinical Epidemiology, Biostatistics and Bioinformatics, Academic Medical Centre, Amsterdam, Netherlands.

Ben Willem J Mol (BWJ)

Department of Obstetrics and Gynaecology, Monash University, Melbourne, Victoria, Australia.

Marjolein Y Berger (MY)

Department of General Practice and Elderly Care Medicine, University of Groningen, University Medical Centre Groningen, Groningen, Netherlands.

Marlies Y Bongers (MY)

Department of Obstetrics and Gynaecology, Máxima MC, Veldhoven, Netherlands; Research School Grow, University of Maastricht, Maastricht, Netherlands.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH